Vargas SMA

Idioma: Español
Referencias bibliográficas: 48
Paginas: 345-351
Archivo PDF: 439.95 Kb.

RESUMEN

El factor de necrosis tumoral alfa (FNT-α) es un regulador clave de la inflamación y un agente crucial en la formación del granuloma. Como tal, una regulación anormal de la función del FNT-α juega un rol importante en el desarrollo de enfermedades inflamatorias crónicas (i.e. Artritis Reumatoide) e infecciones. De allí que las terapias neutralizadoras del FNT-α hayan demostrado una excelente mejoría clínica, bioquímica y radiológica en el tratamiento de las mismas. Sin embargo, la preocupación existe en cuanto a la presencia de mayores efectos adversos dado el papel central que juega el FNT-α en la defensa del huésped, especialmente contra tuberculosis (TB). Hay una estrecha relación temporal droga-efecto para desarrollar TB al usar estos agentes, especialmente con Infliximab, como se demostró en un Meta-análisis. Las guías que propongan el tamizaje del riesgo de infección por tuberculosis latente antes del inicio de Infliximab deben ser diseñadas en cada país tomando en cuenta la epidemiología local. Con investigaciones adicionales, una droga cuyo blanco terapéutico sea el FNT-α con efectos adversos limitados, incluyendo una menor interferencia con la formación del granuloma, debe ser desarrollada.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Balcewicz-Sablinska M., Keane J, Kornfeld H, Remold H. Pathogenic Mycobacterium tuberculosis evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNF-α. J. Immunol. 1998; 161:2636-41

2. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334:1717–25.

3. Bean AG, Roach DR, Briscoe H, France MP, Korner H, Sedgwick JD, et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999;162:3504–11.

4. Bekker LG, Freeman S, Murray PJ, Ryffel B, Kaplan G. TNF-alpha controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J Immunol 2001;166:6728–34.

5. Bongartz T, Sutton A, Sweeting M, Buchan I, Matteson E, Montori V. Anti-TNF antibody therapy in Rheumatoid Arthritis and the risk of serious infections and malignancies: Systematic Review and Meta-analysis of rare harmful effects in Randomized Controlled Trials. JAMA, 2006; 2275-2285, E1.

6. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975;72:3666-70.

7. Centocor I. Remicade (infliximab). Medication Guide approved by the U.S. Food and Drug Administration. Revised October 2006

8. Chan J, Xing Y, Magliozzo RS, Bloom BR. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 1992;175:1111–22.

9. Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.

10. Den Broeder A, Vonkeman H, Creemers M, De Jong E, Van de Laar M. Characteristics of tuberculosis during anti-TNF treatment in RA patients in the netherlands and influence of pre-treatment screening and treatment. Annals of the Rheumatic Diseases 2005;64(Suppl 3):253

11. Ehlers S. Role of tumor necrosis factor (TNF) in host defense against tuberculosis: implications for immunotherapies targeting TNF. Ann Rheum Dis 2003;62 Suppl 2:ii37–42.

12. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003;48:3013–22.

13. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10. (Abstract)

14. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protectiveimmune response against Mycobacterium tuberculosis in mice. Immunity 1995;2:561-72.

15. Food and Drug Administration Center for Biologics Evaluation and Research. Safety update on TNF-α antagonists: Infliximab and etanercept. August 17, 2001.

16. Fratazzi C, Arbeit RD, Carini C, Balcewicz-Sablinska MK, Keane J, Kornfeld H, et al. Macrophage apoptosis in mycobacterial infections. J Leukoc Biol 1999;66:763–4.

17. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents, specifically tumor necrosis factor alpha (TNF alpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases. Ann Rheum Dis 2004; 63(Suppl 2):ii2–ii12.

18. G.E.A.R. Rheumatoid Arthritis Study Group. Tuberculosis in patients treated with anti-TNF-alpha therapy: the Portuguese experience. Annals of the Rheumatic Diseases 2006;65(Suppl 2):498

19. Garcia Vidal C, Rodriguez Fernandez S, Martinez Lacasa J, Salavert M, Vidal R, Rodriguez Carballeira M, et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 2005;40:756–9

20. Gardam MA, Keystone EC, Menzies R et al. Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148–55.

21. Goekoop-Ruiterman YP, Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52:3381- 3390.

22. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arth Rheum 2003;48:2122–7.

23. Haraoui B. Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum. 2005;34(5)(suppl 1):7-11.

24. Keane J, Gershon S, Braun M. Tuberculosis and treatment with infliximab. N Engl J Med 2002;346:623–6.

25. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001;345:1098–104.

26. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 2005; 44: 714–720.

27. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-α therapy. Rheumatology (Oxford). 2003;42:617-621.

28. Krueger G, Callis K. Potential of Tumor Necrosis Factor inhibitors in Psoriasis and Psoriatic arthritis. Arch Dermatol. 2004;140:218-225

29. Ledinghan J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNF-α blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005;44:157–63.

30. Lipsky P, van der Heijde D, St. Clair W, et al. 102-wk clinical and radiologic results from the ATTRACT trial: a 2 year, randomized, controlled, phase 3 trial of infliximab (Remicade®) in patients with active RA despite MTX. Arthritis Rheum 2000;43:(Abstract)S269.

31. Lipsky PE, van der Heijde DMFM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343:1594-1602.

32. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52:3403-3412.

33. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104:487–501.

34. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. (for the ATTRACT Study Group). Lancet 1999;354:1932-39.

35. Mauri DN, Ebner R, Montgomery RI, Kochel KD, Cheung TC, Yu GL, et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator. Immunity 1998;8:21–30.

36. Mease P. Tumor necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 2002;61:298–304

37. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum. 2005;34:12-18

38. Saxne T, Palladino MA Jr, Heinegård D, Talal N, Wollheim FA. Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988;31:1041-5. (Abstract)

39. Shanahan JC, St Clair W. Tumor necrosis factor-alpha blockade: a novel therapy for Rheumatic disease. Clin Immunol 2002;103:231–42.

40. Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis. 2006; 10(10):1127–1132

41. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432-3443.

42. Stenger S. Immunological control of tuberculosis: role of tumor necrosis factor and more. Ann Rheum Dis 2005;64:iv24–iv28.

43. Taylor JC, Orkin R, Lanham J. Tuberculosis following therapy with infliximab may be refractory to antibiotic therapy. Rheumatology 2003;42:901–2.

44. Tetta C, Camussi G, Modena V, Di Vittorio C, Baglioni C. Tumor necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis. 1990;49:665-667. (abstract)

45. Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004;39:1254–5.

46. Wallis RS, Ehlers S. Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum. 2005;34(5)(suppl 1):34-38.

47. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48: 35-45.

48. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372–9.